FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer By Ogkologos - June 27, 2025 294 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the ARANOTE study Source RELATED ARTICLESMORE FROM AUTHOR Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma EMA Recommends Extension of Therapeutic Indications for Retifanlimab MOST POPULAR Persistent Poverty Linked to Increased Risk of Dying from Cancer November 19, 2020 Study Links Breast Cancer Spread to Newly Discovered RNA Splicing Mechanism May 21, 2021 Breast Cancer Surgery Choice May Affect Young Survivors’ Quality of Life September 30, 2021 FDA Approves Selinexor for Relapsed/Refractory Diffuse Large B-Cell Lymphoma June 25, 2020 Load more HOT NEWS Longitudinal Profiling of the Gut Microbiome in Patients Undergoing Immune Checkpoint... What Is Peripheral Neuropathy and How Can It Be Prevented or... Mom Is Warning Other Parents After Her Son Was Bit By... Favourable Response More Likely with Neoadjuvant Dual Immune Checkpoint Inhibitor Than...
